News

TE Connectivity to hold annual general meeting of shareholders on March 12, 2025

GALWAY, Ireland, Jan. 7, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) will hold its 2025 annual general meeting of…

12 months ago

PharmaScroll Launches SocialBI: The Cutting-Edge Social Media Listening Tool for Real-Time Patient Insights

HYDERABAD, India, Jan. 7, 2025 /PRNewswire/ -- PharmaScroll, a renowned market research and business analytics organization is thrilled to announce…

12 months ago

OneOncology Approved by CMS as a Qualified Clinical Data Registry

Oncology Quality Hub Recognized for MIPS Clinical Data Reporting NASHVILLE, Tenn., Jan. 7, 2025 /PRNewswire/ -- OneOncology, the physician-led platform…

12 months ago

Essex Management Appoints David Loose as Chief Executive Officer

Appointment Reflects Commitment to Continuing Essex's Strategic Vision ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ -- Essex Management, an Emmes Group company…

12 months ago

BionicM Announces Launch of U.S. Headquarters and Unveils Bio Leg®, Awarded CES 2025 Best of Innovation

TOKYO, Jan. 7, 2025 /PRNewswire/ -- BionicM (CEO: Sunny Xiaojun Sun, Ph.D) is thrilled to announce the launch of its…

12 months ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Coeptis Secures Five New Clients With Total Contract Value of $1.7 Million Dollars With More On The Horizon Signaling AI-Driven…

12 months ago

Ryght AI and QPS Forge Strategic Partnership to Revolutionize Global Clinical Trials

QPS Selects Ryght AI as Exclusive AI Partner for Clinical Trial Optimization and Automation while adding to Ryght's global site…

12 months ago

High Q Technologies Announces Commercial Availability and First Sale of the FATHOM™ EPR Spectrometer

Proprietary quantum-based sensor and fully automated operation empower structural biologists and drug hunters, furthering High Q's mission of EPR for…

12 months ago

Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI).The partnership with…

12 months ago